Literature DB >> 11371199

EPR investigation of the active site of recombinant human 5-lipoxygenase: inhibition by selenide.

T Hammarberg1, S Kuprin, O Rådmark, A Holmgren.   

Abstract

Lipoxygenases are a group of non-heme iron dioxygenases which catalyze the formation of lipid hydroperoxides from unsaturated fatty acids. 5-Lipoxygenase (5LO) is of particular interest for formation of leukotrienes and lipoxins, implicated in inflammatory processes. In this study, electron paramagnetic resonance (EPR) spectroscopy was used to investigate the active site iron of purified recombinant human 5-lipoxygenase (5LO), and to explore the action of selenide on 5LO. After oxidation by lipid hydroperoxides, 5LO exhibited axial EPR spectra typified by a signal at g = 6.2. However, removal of the lipid hydroperoxides, their metabolites, and the solvent ethanol from the samples resulted in a shift to more rhombic EPR spectra (g = 5.17 and g = 9.0). Thus, many features of 5LO and soybean lipoxygenase-1 EPR spectra were similar, indicating similar flexible iron ligand arrangements in these lipoxygenases. Selenide (1.5 microM) showed a strong inhibitory effect on the enzyme activity of 5LO. In EPR, selenide abolished the signal at g = 6.2, typical for enzymatically active 5LO. Lipid hydroperoxide added to selenide-treated 5LO could not reinstate the signal at g = 6.2, indicating an irreversible change of the coordination of the active site iron.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371199     DOI: 10.1021/bi001595d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Improving protein crystal quality by selective removal of a Ca(2+)-dependent membrane-insertion loop.

Authors:  David B Neau; Nathaniel C Gilbert; Sue G Bartlett; Adam Dassey; Marcia E Newcomer
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-10-24

2.  Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production.

Authors:  Marija Rakonjac; Lutz Fischer; Patrick Provost; Oliver Werz; Dieter Steinhilber; Bengt Samuelsson; Olof Rådmark
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

3.  2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo.

Authors:  C Greiner; C Hörnig; A Rossi; C Pergola; H Zettl; M Schubert-Zsilavecz; D Steinhilber; L Sautebin; O Werz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  5-Lipoxygenase: mechanisms of regulation.

Authors:  Olof Rådmark; Bengt Samuelsson
Journal:  J Lipid Res       Date:  2008-11-05       Impact factor: 5.922

5.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

6.  EPR spectroscopy and electrospray ionization mass spectrometry reveal distinctive features of the iron site in leukocyte 12-lipoxygenase.

Authors:  Johanna Rapp; Shu Xu; Allan M Sharp; Wendell P Griffith; Yong-Wah Kim; Max O Funk
Journal:  Arch Biochem Biophys       Date:  2009-08-14       Impact factor: 4.013

Review 7.  EPR Spectroscopic Studies of Lipoxygenases.

Authors:  Betty J Gaffney
Journal:  Chem Asian J       Date:  2019-12-05

8.  The Intracellular Localisation and Phosphorylation Profile of the Human 5-Lipoxygenase Δ13 Isoform Differs from That of Its Full Length Counterpart.

Authors:  Eric P Allain; Luc H Boudreau; Nicolas Flamand; Marc E Surette
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.